CDMO Live 2025 Highlights: How Bayer, Boehringer Ingelheim, and Leo Pharma are rebuilding manufacturing strategies
- Complexity Challenge: With thousands of SKUs to manage (Bayer handles 5,000+, half outsourced), companies struggle with aging portfolios and aggressive commercial expansion.
- Geopolitical Reshuffling: A staggering 62% of pharma companies are restructuring their manufacturing footprints in response to global tensions.
- Different Resilience Approaches:
- Boehringer Ingelheim (family-owned) maintains dual sourcing despite higher costs
- Leo Pharma focuses on strategic partnerships for smaller-volume products
- Bayer's "Project Martini" shifts from Euro-centric to regional production
- AI Adoption: Still early days, but promising applications in contract management, document processing, and predictive maintenance are emerging.
- Sustainability Shift: While not top priority, sustainability is increasingly viewed as both an ethical necessity and long-term cost reducer.
Bottom Line: The industry is moving from pure cost optimization to balancing affordability with resilience. As Blue Jet Healthcare's MD put it: "resilience is becoming as important as costs."
Download the full report
